Vontobel Holding Ltd. Boosts Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Vontobel Holding Ltd. boosted its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 788.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 195,457 shares of the company’s stock after purchasing an additional 173,457 shares during the quarter. Vontobel Holding Ltd. owned approximately 0.09% of Allogene Therapeutics worth $416,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. abrdn plc bought a new stake in shares of Allogene Therapeutics in the 4th quarter valued at approximately $776,000. Nordea Investment Management AB increased its holdings in shares of Allogene Therapeutics by 2.1% in the 4th quarter. Nordea Investment Management AB now owns 460,641 shares of the company’s stock valued at $986,000 after acquiring an additional 9,635 shares during the last quarter. Barclays PLC increased its holdings in shares of Allogene Therapeutics by 101.5% in the 3rd quarter. Barclays PLC now owns 342,973 shares of the company’s stock valued at $959,000 after acquiring an additional 172,745 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Allogene Therapeutics by 14.4% in the 3rd quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock valued at $9,037,000 after acquiring an additional 407,070 shares during the last quarter. Finally, MML Investors Services LLC bought a new stake in shares of Allogene Therapeutics in the 3rd quarter valued at approximately $56,000. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Allogene Therapeutics

In other news, EVP Zachary Roberts sold 27,199 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total value of $48,414.22. Following the completion of the transaction, the executive vice president now owns 488,054 shares of the company’s stock, valued at approximately $868,736.12. This represents a 5.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Timothy L. Moore sold 14,746 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total value of $25,215.66. Following the completion of the transaction, the insider now directly owns 250,713 shares of the company’s stock, valued at approximately $428,719.23. The trade was a 5.55 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,067 shares of company stock valued at $131,959. 24.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ALLO shares. Piper Sandler lowered their price objective on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. Finally, HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Allogene Therapeutics in a research note on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, Allogene Therapeutics has an average rating of “Moderate Buy” and an average target price of $9.73.

Allogene Therapeutics Stock Performance

NASDAQ:ALLO opened at $2.26 on Friday. Allogene Therapeutics, Inc. has a 1 year low of $1.32 and a 1 year high of $5.78. The stock has a market cap of $473.86 million, a price-to-earnings ratio of -1.45 and a beta of 0.83. The business has a fifty day moving average of $1.96 and a 200-day moving average of $2.37.

Allogene Therapeutics Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).